Mounjaro BMI Eligibility Criteria UK 2026 - From £124.99

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro BMI Eligibility UK 2026 - £124.99

Get Mounjaro at the cheapest UK price from £124.99 with £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro BMI Eligibility Criteria UK 2026: Complete Requirements Guide

Published: 31 August 2026

Understanding mounjaro bmi eligibility criteria uk 2026 is essential before starting tirzepatide treatment, as UK prescribers assess specific BMI thresholds and medical conditions to determine suitability. As of 2026, Mounjaro eligibility in the UK typically requires a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. At Cured Pharmacy, our UK-registered clinical team evaluates each patient against current MHRA-licensed criteria during a comprehensive online assessment, ensuring safe and appropriate prescribing.

What Are the Mounjaro BMI Eligibility Criteria UK 2026?

The mounjaro bmi eligibility criteria uk 2026 follow MHRA-approved prescribing guidelines that prioritise patient safety and clinical appropriateness. For most adults, eligibility requires a body mass index of 30 kg/m² or higher, classified as obese. Alternatively, individuals with a BMI of 27 kg/m² or above may qualify if they have at least one weight-related comorbidity, including type 2 diabetes, dyslipidaemia, hypertension, cardiovascular disease, or obstructive sleep apnoea [1].

These criteria align with the STEP and SURPASS clinical trial inclusion parameters, which demonstrated significant weight reduction outcomes in participants meeting similar BMI thresholds [2]. UK prescribers assess not only BMI but also medical history, current medications, contraindications, and realistic weight management goals. At Cured Pharmacy, superintendent pharmacist Tarun Kumar GPhC 2233073 oversees clinical governance to ensure every prescription adheres to UK regulatory standards and patient-specific needs.

How BMI Calculations Affect Mounjaro BMI Eligibility Criteria UK 2026

BMI is calculated by dividing weight in kilograms by height in metres squared, providing a standardised measure used across UK clinical practice. For mounjaro bmi eligibility criteria uk 2026 assessments, prescribers verify BMI using accurate patient-reported height and weight, often cross-referencing with GP records where available. A BMI of 30 represents the threshold for obesity, while 27 to 29.9 falls into the overweight category with comorbidity considerations.

It is important to note that BMI alone does not determine overall health, and prescribers consider additional factors such as waist circumference, body composition, and metabolic health markers. Patients with a BMI slightly below 27 may still be considered on a case-by-case basis if they present significant weight-related health risks. Cured Pharmacy's online consultation captures comprehensive health data to support informed prescribing decisions aligned with current UK guidelines.

Adjustments for Ethnicity and Health Conditions

NICE guidance recommends lower BMI thresholds for individuals of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds due to increased metabolic risk at lower BMI levels [3]. For these populations, a BMI of 27.5 or above may be considered equivalent to 30, and 23 or above with comorbidities equivalent to 27. These adjustments reflect evidence that certain ethnic groups experience higher rates of type 2 diabetes and cardiovascular disease at lower body weights, making mounjaro bmi eligibility criteria uk 2026 more inclusive and clinically appropriate.

Comorbidities That Influence Mounjaro BMI Eligibility Criteria UK 2026

The mounjaro bmi eligibility criteria uk 2026 extend beyond BMI alone, recognising that weight-related comorbidities significantly impact treatment suitability. Patients with type 2 diabetes, prediabetes, hypertension, dyslipidaemia, non-alcoholic fatty liver disease, polycystic ovary syndrome, or obstructive sleep apnoea may qualify at a lower BMI threshold of 27 [4]. These conditions are strongly associated with excess weight and metabolic dysfunction, and clinical trials have shown that tirzepatide can improve glycaemic control, blood pressure, and lipid profiles alongside weight reduction.

During the online assessment at Cured Pharmacy, patients are asked to disclose all diagnosed medical conditions and current medications. This information allows UK prescribers to evaluate whether Mounjaro is both safe and likely to provide clinical benefit. Patients with cardiovascular risk factors or metabolic syndrome may be prioritised for treatment, as weight loss via GLP-1 and GIP receptor agonism can reduce long-term health complications.

Treatment Type Typical BMI Eligibility Starting Price
Mounjaro (Tirzepatide) GLP-1/GIP injection ≥30 or ≥27 with comorbidities from £145.00
Wegovy (Semaglutide) GLP-1 injection ≥30 or ≥27 with comorbidities from £89.00
Wegovy Oral Tablets GLP-1 tablet ≥30 or ≥27 with comorbidities from £83.00
Saxenda (Liraglutide) GLP-1 injection ≥30 or ≥27 with comorbidities from £68.00
Orlistat Lipase inhibitor ≥30 or ≥28 with risk factors from £32.00
Mysimba Combination tablet ≥30 or ≥27 with comorbidities from £125.95

NHS Versus Private Mounjaro BMI Eligibility Criteria UK 2026

NHS access to Mounjaro for weight management remains limited as of 2026, with availability primarily restricted to specialist weight management services and type 2 diabetes clinics. NHS eligibility criteria may be more stringent, often requiring participation in structured lifestyle programmes and evidence of unsuccessful weight loss attempts before tirzepatide is considered. Private prescribing, such as through Cured Pharmacy, follows MHRA-licensed criteria and allows faster access for eligible patients without lengthy waiting lists.

Private mounjaro bmi eligibility criteria uk 2026 assessments are conducted by UK-registered prescribers who evaluate the same clinical parameters as NHS practitioners but can offer treatment without the additional administrative barriers. Patients choosing private care benefit from transparent upfront pricing, with Mounjaro available from £124.99 at Cured Pharmacy, and the convenience of online consultations completed in under three minutes. All prescriptions are subject to clinical approval, ensuring responsible and evidence-based prescribing.

Regulatory Oversight and Patient Safety

Cured Pharmacy operates under GPhC registration 9012511, adhering to strict UK pharmacy regulations and clinical governance frameworks. Every Mounjaro prescription is reviewed by a qualified UK prescriber, and patients receive genuine MHRA-licensed medications sourced from reputable UK-licensed wholesalers. This regulatory oversight ensures that mounjaro bmi eligibility criteria uk 2026 are applied consistently and safely, protecting patient welfare and maintaining professional standards.

How to Assess Your Mounjaro BMI Eligibility Criteria UK 2026 Status

To determine if you meet mounjaro bmi eligibility criteria uk 2026, start by calculating your BMI using an online calculator or the formula: weight (kg) ÷ height (m)². If your BMI is 30 or above, you likely meet the primary criterion. If your BMI is between 27 and 29.9, review whether you have any weight-related health conditions such as type 2 diabetes, high blood pressure, or sleep apnoea, which may support eligibility at this lower threshold.

Cured Pharmacy's online consultation includes a detailed health questionnaire that captures BMI, medical history, current medications, and weight management goals. UK prescribers review this information and may request additional details or recommend alternative treatments if Mounjaro is not suitable. The assessment process is designed to be thorough yet efficient, with most patients receiving a prescribing decision within hours. Patients who do not meet mounjaro bmi eligibility criteria uk 2026 may be offered alternative weight management options such as Wegovy, Saxenda, or Orlistat, depending on individual clinical profiles.

Updated Mounjaro BMI Eligibility Criteria UK 2026 and Future Changes

As of 2026, mounjaro bmi eligibility criteria uk 2026 remain aligned with MHRA licensing terms and NICE guidance on obesity management. Ongoing real-world evidence and post-marketing surveillance continue to inform prescribing practices, with potential future updates to eligibility thresholds based on emerging safety and efficacy data. The SURMOUNT clinical trial programme, which evaluated tirzepatide specifically for weight management in non-diabetic adults, demonstrated average weight reductions of up to 22.5% at the highest dose, supporting broader use in obesity treatment [5].

Patients considering Mounjaro should stay informed about any regulatory updates, though current criteria are expected to remain stable throughout 2026. Cured Pharmacy's clinical team monitors MHRA guidance and adjusts prescribing protocols accordingly, ensuring all patients receive care based on the latest evidence and regulatory standards. For those who qualify, Mounjaro offers a clinically proven option for achieving meaningful weight loss when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity.

Long-Term Monitoring and Ongoing Eligibility

Continued eligibility for Mounjaro treatment depends on achieving and maintaining clinically significant weight loss, typically defined as at least 5% reduction in initial body weight within the first 12 weeks of treatment [6]. UK prescribers may discontinue treatment if weight loss targets are not met or if adverse effects outweigh benefits. Regular follow-up consultations allow prescribers to monitor progress, adjust dosing, and ensure ongoing suitability for mounjaro bmi eligibility criteria uk 2026 standards.

Scientific References

  1. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. UK Medicines and Healthcare products Regulatory Agency. [accessed 31 August 2026]
  2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 31 August 2026]
  3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. [accessed 31 August 2026]
  4. Garvey, W. T., Mechanick, J. I., Brett, E. M., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 22(Suppl 3), 1-203. [accessed 31 August 2026]
  5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 31 August 2026]
  6. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 31 August 2026]
  7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 31 August 2026.
  8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 31 August 2026.
  9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 31 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What is the minimum BMI for Mounjaro eligibility in the UK in 2026?
The mounjaro bmi eligibility criteria uk 2026 typically require a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as type 2 diabetes or hypertension, subject to prescriber assessment.
Can I get Mounjaro with a BMI under 27 in the UK?
Generally, mounjaro bmi eligibility criteria uk 2026 do not permit prescribing below a BMI of 27 unless exceptional clinical circumstances exist, and all prescriptions require individual assessment by a UK-registered prescriber.
Do ethnicity adjustments apply to Mounjaro BMI eligibility criteria UK 2026?
Yes, NICE guidance recommends lower BMI thresholds for South Asian, Chinese, and other ethnic groups at higher metabolic risk, meaning mounjaro bmi eligibility criteria uk 2026 may apply at BMI 27.5 or 23 with comorbidities for these populations.
What comorbidities qualify me for Mounjaro at BMI 27?
Weight-related conditions such as type 2 diabetes, prediabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease may support mounjaro bmi eligibility criteria uk 2026 at a lower BMI threshold of 27.
Is Mounjaro available on the NHS in 2026?
NHS access to Mounjaro for weight management remains limited in 2026, with most patients accessing treatment privately through registered UK pharmacies like Cured Pharmacy, where mounjaro bmi eligibility criteria uk 2026 are assessed by qualified prescribers.
How quickly can I get Mounjaro if I meet the BMI criteria?
At Cured Pharmacy, eligible patients who meet mounjaro bmi eligibility criteria uk 2026 can complete an online consultation in under three minutes, with prescribing decisions typically made within hours and next-day delivery available.
Will my BMI be rechecked during Mounjaro treatment?
Yes, ongoing mounjaro bmi eligibility criteria uk 2026 assessments include monitoring weight loss progress, and prescribers may discontinue treatment if clinically significant weight reduction is not achieved within 12 weeks.
Can I use Mounjaro if I have tried other weight loss treatments?
Previous use of other weight loss medications does not disqualify you from Mounjaro, and meeting mounjaro bmi eligibility criteria uk 2026 depends primarily on current BMI, comorbidities, and overall health status as assessed by a UK prescriber.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 31 August 2026

Last updated on 31 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 31 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (31 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.